TransThera Sciences (Nanjing) Inc.
HKSE: 2617.HK0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Hong Kong Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Frank Yongqian Wu
- Employees
- 121
- Headquarters
- Nanjing, China
- IPO year
- 2025
- Market cap
- HK$21.9B
- Website
- https://www.transtherabio.com
Loading 2617…
Loading profile data…Frequently asked questions about 2617
What does TransThera Sciences (Nanjing) Inc. (2617.HK) do?
TransThera Sciences (Nanjing), Inc., clinical stage biopharmaceutical company, discovers, develops, and commercializes small molecule therapies for oncology, inflammatory, and cardiometabolic diseases. The company provides Tinengotinib (TT-00420), a MTK inhibitor for the treatment of drug-resistant, relapsed, or refractory cancers. It also devel...
Where does 2617.HK trade?
TransThera Sciences (Nanjing) Inc. (2617.HK) trades on the Hong Kong Stock Exchange.
What sector is 2617.HK in?
TransThera Sciences (Nanjing) Inc. (2617.HK) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of TransThera Sciences (Nanjing) Inc.?
Frank Yongqian Wu is the chief executive officer of TransThera Sciences (Nanjing) Inc. (2617.HK).
Where is TransThera Sciences (Nanjing) Inc. headquartered?
TransThera Sciences (Nanjing) Inc. is headquartered in China.
Does 2617.HK pay a dividend?
TransThera Sciences (Nanjing) Inc. (2617.HK) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 2617.HK go public?
TransThera Sciences (Nanjing) Inc. (2617.HK) completed its initial public offering in 2025.